Overview

A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets

Status:
RECRUITING
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
A Phase III clinical study evaluating the efficacy and safety of cabergoline tablets versus bromocriptine mesylate tablets in patients with hyperprolactinemia
Phase:
PHASE3
Details
Lead Sponsor:
Changchun GeneScience Pharmaceutical Co., Ltd.
Treatments:
Bromocriptine
Cabergoline